CHLORAMPHENICOL MONOETHANOLAMINE SUCCINATE

First approved in 1950

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C11H12Cl2N2O5.C4H6O4.C2H7NO
Molecular Weight	502.301
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of CHLORAMPHENICOL MONOETHANOLAMINE SUCCINATE

Structure Search

SMILES

NCCO.OC(=O)CCC(O)=O.OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O

InChI

InChIKey=GLOVPJIOQKHINH-UONRGADFSA-N

InChI=1S/C11H12Cl2N2O5.C4H6O4.C2H7NO/c12-10(13)11(18)14-8(5-16)9(17)6-1-3-7(4-2-6)15(19)20;5-3(6)1-2-4(7)8;3-1-2-4/h1-4,8-10,16-17H,5H2,(H,14,18);1-2H2,(H,5,6)(H,7,8);4H,1-3H2/t8-,9-;;/m1../s1

HIDE SMILES / InChI

Molecular Formula	C2H7NO
Molecular Weight	61.0831
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C11H12Cl2N2O5
Molecular Weight	323.129
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C4H6O4
Molecular Weight	118.088
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.acutetox.eu/pdf_human_short/74-Chloramphenicol%20revised.pdf | https://www.ncbi.nlm.nih.gov/pubmed/20930076

Chloramphenicol is a broad-spectrum antibiotic that was first isolated from Streptomyces venezuelae in 1947. The drug was subsequently chemically synthesized. It has both a bacteriostatic and bactericidal effect; in the usual therapeutic concentrations it is bacteriostatic. Chloramphenicol is used for the treatment of serious gram-negative, gram-positive, and anaerobic infections. It is especially useful in the treatment of meningitis, typhoid fever, and cystic fibrosis. It should be reserved for infections for which other drugs are ineffective or contraindicated. Chloramphenicol, a small inhibitor of bacterial protein synthesis, is active against a variety of bacteria and readily enters the CSF. It has been used extensively in the last decades for the treatment of bacterial meningitis. In industrialized countries, chloramphenicol is restricted mostly to topical uses because of the risk of induction of aplastic anemia. However, it remains a valuable reserve antibiotic for patients with allergy to β-lactam antibiotics or with CNS infections caused by multiresistant pathogens.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Target ID: intestinal esterase Sources: https://www.iasj.net/iasj?func=article&aId=41875	Substrate 656
Bacterial 70S ribosome 179 Target ID: CHEMBL2363135 Sources: https://www.ncbi.nlm.nih.gov/pubmed/4599122 \| https://www.ncbi.nlm.nih.gov/pubmed/324517	Inhibitor 8228

Conditions

Condition	Modality	Targets	Highest Phase	Product
Eye infections 13 Sources: https://www.medicines.org.uk/emc/PIL.29903.latest.pdf	Curative		Approved 8360	CHLOROPTIC Approved Use Indications and Usage In accord with the concepts in the Warning Box and this section, chloramphenicolmust be used only in those serious infections for which less potentially dangerous drugs are ineffective or contraindicated. However, chloramphenicol may be chosen to initiate antibiotic therapy on the clinical impression that one of the conditions below is believed to be present; in vitro sensitivity tests should be performed concurrently so that the drug may be discontinued as soon as possible if less potentially dangerous agents are indicated by such tests. The decision to continue use of chloramphenicol rather than another antibiotic when both are suggested by in vitro studies to be effective against a specific pathogen should be based upon severity of the infection, susceptibility of the pathogen to the various antimicrobial drugs, efficacy of the various drugs in the infection, and the important additional concepts contained in the Warning Box above. 1. Acute infections caused by Salmonella typhi* It is not recommended for the routine treatment of the typhoid carrier state. 2. Serious infections caused by susceptible strains in accordance with the concepts expressed above: a) Salmonella species b) H. influenzae, specially meningeal infections c) Rickettsia d) Lymphogranuloma-psittacosis group e) Various gram-negative bacteria causing bacteremia, meningitis, or other serious gram-negative infections f) Other susceptible organisms which have been demonstrated to be resistant to all other appropriate antimicrobial agents. 3. Cystic fibrosis regimens *In treatment of typhoid fever some authorities recommend that chloramphenicol be administered at therapeutic levels for 8 to 10 days after the patient has become afebrile to lessen the possibility of relapse. Launch Date -5.63328E10

C_max

Value	Dose	Co-administered	Analyte	Population
16.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2713219/	500 mg 4 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:		CHLORAMPHENICOL blood	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
59.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2713219/	500 mg 4 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:		CHLORAMPHENICOL blood	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
3.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2713219/	500 mg 4 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CHLORAMPHENICOL blood	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
5.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7463235/	25 mg/kg 4 times / day multiple, intravenous dose: 25 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:	CHLORAMPHENICOL serum	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN
2.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7463235/	25 mg/kg 4 times / day multiple, intravenous dose: 25 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:	CHLORAMPHENICOL SUCCINATE serum	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.5 % 4 times / day multiple, ophthalmic Recommended Dose: 0.5 %, 4 times / day Route: ophthalmic Route: multiple Dose: 0.5 %, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15993231/	unhealthy, 0.5 - 12 years n = 163 Health Status: unhealthy Condition: acute infective conjunctivitis Age Group: 0.5 - 12 years Sex: unknown Population Size: 163 Sources: https://pubmed.ncbi.nlm.nih.gov/15993231/	Other AEs: Swollen eyelid... Other AEs: Swollen eyelid (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/15993231/
0.25 g 1 times / 3 months multiple, intramuscular Recommended Dose: 0.25 g, 1 times / 3 months Route: intramuscular Route: multiple Dose: 0.25 g, 1 times / 3 months Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 11 years n = 1 Health Status: unhealthy Condition: infection Age Group: 11 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	Disc. AE: Aplastic anemia... AEs leading to discontinuation/dose reduction: Aplastic anemia (grade 4, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/
70 mg/kg 1 times / day steady, intravenous Recommended Dose: 70 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 70 mg/kg, 1 times / day Co-administed with:: (meropenem) 120 mg/kg/day Sources: https://pubmed.ncbi.nlm.nih.gov/28186714/	unhealthy, 15 years n = 1 Health Status: unhealthy Condition: Cystic Fibrosis and infection Age Group: 15 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/28186714/	Disc. AE: Hyperlactatemia... AEs leading to discontinuation/dose reduction: Hyperlactatemia (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/28186714/
3 g 1 times / day multiple, intravenous Recommended Dose: 3 g, 1 times / day Route: intravenous Route: multiple Dose: 3 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 23 years n = 1 Health Status: unhealthy Condition: infection Age Group: 23 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	Disc. AE: Aplastic anemia... AEs leading to discontinuation/dose reduction: Aplastic anemia (grade 5, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/
2.5 g 1 times / day multiple, intravenous Recommended Dose: 2.5 g, 1 times / day Route: intravenous Route: multiple Dose: 2.5 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 27 years n = 1 Health Status: unhealthy Condition: infection Age Group: 27 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	Disc. AE: Aplastic anemia... AEs leading to discontinuation/dose reduction: Aplastic anemia (grade 4, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/
1 g 1 times / day multiple, parenteral Recommended Dose: 1 g, 1 times / day Route: parenteral Route: multiple Dose: 1 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 39 years n = 1 Health Status: unhealthy Condition: infection Age Group: 39 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	Disc. AE: Aplastic anemia... AEs leading to discontinuation/dose reduction: Aplastic anemia (grade 4, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/
750 mg 4 times / day steady, intravenous Recommended Dose: 750 mg, 4 times / day Route: intravenous Route: steady Dose: 750 mg, 4 times / day Co-administed with:: tobramycin nafcillin Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 54 years n = 1 Health Status: unhealthy Condition: purulent drainage from the surgical wound Age Group: 54 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	Disc. AE: Aplastic anemia... AEs leading to discontinuation/dose reduction: Aplastic anemia (grade 5, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/
4 g 1 times / day multiple, intravenous Recommended Dose: 4 g, 1 times / day Route: intravenous Route: multiple Dose: 4 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 61 years n = 1 Health Status: unhealthy Condition: infection Age Group: 61 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	Disc. AE: Aplastic anemia... AEs leading to discontinuation/dose reduction: Aplastic anemia (grade 5, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/
1 g 1 times / day multiple, intramuscular Recommended Dose: 1 g, 1 times / day Route: intramuscular Route: multiple Dose: 1 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 68 years n = 1 Health Status: unhealthy Condition: infection Age Group: 68 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	Disc. AE: Aplastic anemia... AEs leading to discontinuation/dose reduction: Aplastic anemia (grade 4, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/
2 g 1 times / day multiple, parenteral Recommended Dose: 2 g, 1 times / day Route: parenteral Route: multiple Dose: 2 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 71 years n = 1 Health Status: unhealthy Condition: infection Age Group: 71 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	Disc. AE: Aplastic anemia... AEs leading to discontinuation/dose reduction: Aplastic anemia (grade 5, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/
3 % 1 times / day multiple, topical Recommended Dose: 3 %, 1 times / day Route: topical Route: multiple Dose: 3 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33378750/	unhealthy, adult n = 23 Health Status: unhealthy Condition: cancer patients with (EGFRI)-induced papulopustular rash Age Group: adult Sex: unknown Population Size: 23 Sources: https://pubmed.ncbi.nlm.nih.gov/33378750/	Sources: https://pubmed.ncbi.nlm.nih.gov/33378750/

AEs

AE	Significance	Dose	Population
Swollen eyelid	1 patient	0.5 % 4 times / day multiple, ophthalmic Recommended Dose: 0.5 %, 4 times / day Route: ophthalmic Route: multiple Dose: 0.5 %, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15993231/	unhealthy, 0.5 - 12 years n = 163 Health Status: unhealthy Condition: acute infective conjunctivitis Age Group: 0.5 - 12 years Sex: unknown Population Size: 163 Sources: https://pubmed.ncbi.nlm.nih.gov/15993231/
Aplastic anemia	grade 4, 1 patient Disc. AE	0.25 g 1 times / 3 months multiple, intramuscular Recommended Dose: 0.25 g, 1 times / 3 months Route: intramuscular Route: multiple Dose: 0.25 g, 1 times / 3 months Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 11 years n = 1 Health Status: unhealthy Condition: infection Age Group: 11 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/
Hyperlactatemia	1 patient Disc. AE	70 mg/kg 1 times / day steady, intravenous Recommended Dose: 70 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 70 mg/kg, 1 times / day Co-administed with:: (meropenem) 120 mg/kg/day Sources: https://pubmed.ncbi.nlm.nih.gov/28186714/	unhealthy, 15 years n = 1 Health Status: unhealthy Condition: Cystic Fibrosis and infection Age Group: 15 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/28186714/
Aplastic anemia	grade 5, 1 patient Disc. AE	3 g 1 times / day multiple, intravenous Recommended Dose: 3 g, 1 times / day Route: intravenous Route: multiple Dose: 3 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 23 years n = 1 Health Status: unhealthy Condition: infection Age Group: 23 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/
Aplastic anemia	grade 4, 1 patient Disc. AE	2.5 g 1 times / day multiple, intravenous Recommended Dose: 2.5 g, 1 times / day Route: intravenous Route: multiple Dose: 2.5 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 27 years n = 1 Health Status: unhealthy Condition: infection Age Group: 27 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/
Aplastic anemia	grade 4, 1 patient Disc. AE	1 g 1 times / day multiple, parenteral Recommended Dose: 1 g, 1 times / day Route: parenteral Route: multiple Dose: 1 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 39 years n = 1 Health Status: unhealthy Condition: infection Age Group: 39 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/
Aplastic anemia	grade 5, 1 patient Disc. AE	750 mg 4 times / day steady, intravenous Recommended Dose: 750 mg, 4 times / day Route: intravenous Route: steady Dose: 750 mg, 4 times / day Co-administed with:: tobramycin nafcillin Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 54 years n = 1 Health Status: unhealthy Condition: purulent drainage from the surgical wound Age Group: 54 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/
Aplastic anemia	grade 5, 1 patient Disc. AE	4 g 1 times / day multiple, intravenous Recommended Dose: 4 g, 1 times / day Route: intravenous Route: multiple Dose: 4 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 61 years n = 1 Health Status: unhealthy Condition: infection Age Group: 61 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/
Aplastic anemia	grade 4, 1 patient Disc. AE	1 g 1 times / day multiple, intramuscular Recommended Dose: 1 g, 1 times / day Route: intramuscular Route: multiple Dose: 1 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 68 years n = 1 Health Status: unhealthy Condition: infection Age Group: 68 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/
Aplastic anemia	grade 5, 1 patient Disc. AE	2 g 1 times / day multiple, parenteral Recommended Dose: 2 g, 1 times / day Route: parenteral Route: multiple Dose: 2 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/	unhealthy, 71 years n = 1 Health Status: unhealthy Condition: infection Age Group: 71 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/3055188/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1579		inhibitor 1837

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A 72 CYP2A6 704 CYP2B6 799 CYP2C19 1463 CYP2E1 876 CYP2C8/9 44

Drug as perpetrator

Target	Modality	Activity
CYP2D6 1875	inhibitor 3240 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC253795/	no [IC50 375.9 uM]
CYP1A 121	inhibitor 3240 Sources: https://www.info.pmda.go.jp/go/interview/2/530258_6151401F1033_2_002_1F.pdf#page=18 Page: Product Information Sheet in Japanese) 18	no
CYP2A6 736	inhibitor 3240 Sources: https://www.info.pmda.go.jp/go/interview/2/530258_6151401F1033_2_002_1F.pdf#page=18 Page: Product Information Sheet in Japanese) 18	no
CYP2B6 985	inhibitor 3240 Sources: https://www.info.pmda.go.jp/go/interview/2/530258_6151401F1033_2_002_1F.pdf#page=18 Page: Product Information Sheet in Japanese) 18	no
CYP2C8/9 44	inhibitor 3240 Sources: https://www.info.pmda.go.jp/go/interview/2/530258_6151401F1033_2_002_1F.pdf#page=18 Page: Product Information Sheet in Japanese) 18	no
CYP2E1 964	inhibitor 3240 Sources: https://www.info.pmda.go.jp/go/interview/2/530258_6151401F1033_2_002_1F.pdf#page=18 Page: Product Information Sheet in Japanese) 18	no
CYP2C19 1537	inhibitor 3240 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC253795/, https://www.info.pmda.go.jp/go/interview/2/530258_6151401F1033_2_002_1F.pdf#page=18 Page: Product Information Sheet in Japanese) 18	yes [IC50 32 uM]
CYP3A4 1909	inhibitor 3240 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC253795/	yes [IC50 48.1 uM]

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B2-0144	http://www.3bsc.com/index/pro_info.php?id=19500
3B Scientific (Wuhan) Corp	3B1-01359	http://www.3bsc.com/index/pro_info.php?id=21571
3B Scientific (Wuhan) Corp	3B1-01423	http://www.3bsc.com/index/pro_info.php?id=21635
AHH Chemical co.,ltd	API-1130	http://www.ahhchemical.com/product/API-1130.html
AK Scientific, Inc. (AKSCI)	M163	http://www.aksci.com/item_detail.php?cat=M163
AbMole Bioscience	M4901	http://www.abmole.com/products/chloramphenicol.html
Achemo Scientific Limited	AC-11414	http://www.achemo.com/product_view.asp?ID=1304
Achemtek	0104-014718	http://www.achemtek.com/56-75-7
Acros Organics	AC227920250	https://www.fishersci.com/shop/products/chloramphenicol-98-acros-organics-1/AC227920250
Acros Organics	AC227925000	https://www.fishersci.com/shop/products/chloramphenicol-98-acros-organics-2/AC227925000
Acros Organics	AC227921000	https://www.fishersci.com/shop/products/chloramphenicol-98-acros-organics/AC227921000
Adooq BioScience	A10200	https://www.adooq.com/chloramphenicol.html
Alfa Aesar	B20841	https://www.alfa.com/en/catalog/B20841/
Alfa Chemistry	AP56757-A	https://reagents.alfa-chemistry.com/product/chloramphenicol-cas-56-75-7-13261.html
Alfa Chemistry	AP56757-B	https://reagents.alfa-chemistry.com/product/chloramphenicol-cas-56-75-7-13262.html
Angene	AGN-PC-0SMDXX	http://www.angenechemical.com/productshow/AGN-PC-0SMDXX.html
ApexBio Technology	A2512	http://www.apexbt.com/chloramphenicol.html
Aronis	ARONIS23913	http://www.aronis.ru/store/index.php?main_page=product_info&cPath=1&products_id=1185
Aurora Fine Chemicals LLC	K04.629.929	http://online.aurorafinechemicals.com/info?ID=K04.629.929
Aurum Pharmatech LLC	W-2830	http://www.Aurumpharmatech.com/Product/ProductDetails/W_2830
Avantor Inc	200002-782	https://us.vwr.com/store/product/7517958/chloramphenicol
Avantor Inc	101094-576	https://us.vwr.com/store/product/7889372/chloramphenicol
BioChemPartner	BCP12150	http://www.biochempartner.com/56-75-7-BCP12150
BioSynth	C-3307	https://www.biosynth.com/en/products/life-science/culture-media-additives/products/C-3307.html
Calbiochem	220551	http://www.emdbiosciences.com/product/220551
Capot Chemical	20321	http://www.capotchem.com/en/20321.htm
Capot Chemical	PubChem20321	http://www.capotchem.com/en/20321.htm
Chem Scene	CS-2207	http://www.chemscene.com/56-75-7.html
ChemMol	80101190	http://www.chemmol.com/chemmol/80101190.html
ChemMol	99159330	http://www.chemmol.com/chemmol/99159330.html
Chemenu	CM110456	http://www.chemenu.com/products/CM110456
Chemspace	CSSB00000037240	https://chem-space.com/CSSB00000037240
Chiralblock Biosciences	CB11330	http://www.chiralblock.com/products/56-75-7.html
Clearsynth	CS-O-11618	https://www.clearsynth.com/en/CSO11618.html
DC Chemicals	DCAPI1255	http://www.dcchemicals.com//product_show-Chloramphenicol_Chloromycetin_.html
EMD Millipore	220551	http://www.emdbiosciences.com/product/220551
Glentham Life Sciences	GA0258	http://www.glentham.com/products/product/GA0258/
LGC Standards	DRE-C11120000	https://www.lgcstandards.com/US/en/p/DRE-C11120000
LGC Standards	DRE-L11120000AL	https://www.lgcstandards.com/US/en/p/DRE-L11120000AL
LGC Standards	DRE-XA11120000EA	https://www.lgcstandards.com/US/en/p/DRE-XA11120000EA
LGC Standards	LGCFOR0516.00	https://www.lgcstandards.com/US/en/p/LGCFOR0516.00
LGC Standards	MM0516.00	https://www.lgcstandards.com/US/en/p/MM0516.00
Lab Network	LN00159574	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00159574
Matrix Scientific	58319	https://www.matrixscientific.com/058319.html
MedChem Express	HY-B0239	https://www.medchemexpress.com/Chloramphenicol.html
MuseChem	A001107	https://www.musechem.com/product/A001107.html
MuseChem	M114534	https://www.musechem.com/product/M114534.html
Oakwood	492377	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=193461&ExtHyperLink=1
Sigma-Aldrich	23276_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/23276?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	31667_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/31667?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	75565_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/75565?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	BP854_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/bp854?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	1107004_USP	https://www.sigmaaldrich.com/catalog/product/usp/1107004?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S772648	https://www.smolecule.com/products/s772648
Synblock Inc	AB02994	http://www.synblock.com/product/56-75-7.html
TCI (Tokyo Chemical Industry)	C2255	http://www.tcichemicals.com/eshop/en/us/commodity/C2255/index.html
THE BioTek	bt-295295	https://www.thebiotek.com/product/others/bt-295295
THE BioTek	bt-458998	https://www.thebiotek.com/product/others/bt-458998
VladaChem	VL141192	https://www.vladachem.com/product.php?products=56-75-7
abcr GmbH	AB125782	http://www.abcr.com/shop/en/AB125782
eNovation Chemicals	D397703	http://www.enovationchem.com/productDetails.asp?productID=D397703
iChemical	EBD2198129	http://www.ichemical.com/products/56-75-7.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
mcule	MCULE-7778960570	https://mcule.com/MCULE-7778960570/

PubMed

Title	Date	PubMed
Survey of yeast mastitis in dairy herds of small-type farms in the Lublin region, Poland.	2001	11392567
Carbon and nitrogen removal from a wastewater of an industrial dairy laboratory with a coupled anaerobic filter-sequencing batch reactor system.	2001	11381913
Amplification of the Escherichia coli lacZ gene in Bacillus subtilis and its expression on a by-product growth medium.	2001	11314242
Comparative review of topical ophthalmic antibacterial preparations.	2001	11270936
The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs.	2001	11248841
Disposition kinetics of florfenicol in goats by using two analytical methods.	2001 Apr	11379386
Prevalence of penicillin-resistant Streptococcus pneumoniae in Kuwait.	2001 Apr	11330362
Antimicrobial resistance of Streptococcus pneumoniae at a university hospital in Saudi Arabia.	2001 Apr	11330361
Strain differences in haematological response to chloramphenicol succinate in mice: implications for toxicological research.	2001 Apr	11295484
Randomised controlled trial of ketorolac in the management of corneal abrasions.	2001 Apr	11284758
Intraabdominal vancomycin-resistant enterococcus infections: the new threat.	2001 Apr	11276278
Toxicity of natural tear substitutes in a fully defined culture model of human corneal epithelial cells.	2001 Apr	11274071
Activity of moxifloxacin against clinical isolates of Streptococcus pneumoniae from England and Wales.	2001 Apr	11266412
The epithelial flap for photorefractive keratectomy.	2001 Apr	11264125
Sex-related differences in antinociception and tolerance development following chronic intravenous infusion of morphine in the rat: modulatory role of testosterone via morphine clearance.	2001 Apr	11259573
An outbreak of Salmonella enteritidis infection in pygmy hogs (Sus salvanius).	2001 Apr	11254078
Plasmid transfer and susceptibility to antibiotics in the halophilic phototrophs Rhodovibrio salinarum and Rhodothalassium salexigens.	2001 Apr 1	11287156
Streptococcus pneumoniae nasopharyngeal carriage prevalence, serotype distribution, and resistance patterns among children on Lombok Island, Indonesia.	2001 Apr 1	11264032
UV-induced increase in RNA polymerase activity in Xanthomonas oryzae pathovar oryzae.	2001 Aug	11391475
Molecular epidemiology of multiple drug resistant type 6B Streptococcus pneumoniae in the Northern Territory and Queensland, Australia.	2001 Feb	11293678
Improved high performance liquid chromatographic analysis of omeprazole in human plasma.	2001 Feb	11272330
Effect of highly bioaccumulated polychlorinated biphenyl congeners on estrogen and androgen receptor activity.	2001 Feb 14	11275356
A limited loss of DNA compaction accompanying the release of cytoplasm from cells of Escherichia coli.	2001 Jan	11356066
Chloramphenicol treatment for vancomycin-resistant Enterococcus faecium bacteremia.	2001 Jan	11284938
Inactivation of chloramphenicol by Staphylococcus aureus biotype C from humans & animals.	2001 Jan	11280165
Interaction of human aldehyde dehydrogenase with aromatic substrates and ligands.	2001 Jan 30	11306037
Lack of evidence for chloramphenicol resistance in Neisseria meningitidis, Africa.	2001 Jan-Feb	11266315
Drug resistant Haemophilus influenzae from respiratory tract infection in a tertiary care hospital in north India.	2001 Jan-Mar	11370501
Antibacterial activity of 4,5-dihydroxy-2-cyclopentan-1-one (DHCP) and cloning of a gene conferring DHCP resistance in Escherichia coli.	2001 Jul	11361079
A novel heat shock protein plays an important role in thermal stress management in cyanobacteria.	2001 Jul 6	11342543
Cloning and functional analysis of a phosphopantetheinyl transferase superfamily gene associated with jadomycin biosynthesis in Streptomyces venezuelae ISP5230.	2001 Jun	11390684
Distribution of resistance genes tet(M), aph3'-III, catpC194 and the integrase gene of Tn1545 in clinical Streptococcus pneumoniae harbouring erm(B) and mef(A) genes in Spain.	2001 Jun	11389119
External quality assessment of antimicrobial susceptibility testing in Europe.	2001 Jun	11389112
Secretion of the virulence-associated Campylobacter invasion antigens from Campylobacter jejuni requires a stimulatory signal.	2001 Jun 1	11343209
[Susceptibility of non-typhi Salmonella spp. at the Galdakao Hospital (1992-1998)].	2001 Mar	11376350
Analysis of a conserved hydrophobic pocket important for the thermostability of Bacillus pumilus chloramphenicol acetyltransferase (CAT-86).	2001 Mar	11342712
Occurrence of the vanA and vanC2/C3 genes in Enterococcus species isolated from poultry sources in Malaysia.	2001 Mar	11337180
Antimicrobial susceptibilities of Erysipelothrix rhusiopathiae isolated from pigs with swine erysipelas in Japan, 1988-1998.	2001 Mar	11315521
Antimicrobial susceptibility of Listeria monocytogenes isolated from meningoencephalitis in sheep.	2001 Mar	11282267
Antimicrobial resistance of Enterococci in Lebanon.	2001 Mar	11282266
Improved agar diffusion method for detecting residual antimicrobial agents.	2001 Mar	11252480
Clostridium sordelii corneal ulcer.	2001 Mar-Apr	11339473
Induction of complement sensitivity in Escherichia coli by citric acid and low pH.	2001 May	11348438
In vitro susceptibility to 15 antibiotics of vibrios isolated from penaeid shrimps in Northwestern Mexico.	2001 May	11337225
Carriage of antibiotic-resistant bacteria by healthy children.	2001 May	11328771
Chromate tolerant bacteria isolated from tannery effluent.	2001 May	11265785
Neisseria meningitidis with decreased susceptibility to penicillin in Ontario, Canada 1997-2000.	2001 May 1	11381628
Increased mitochondrial-encoded gene transcription in immortal DF-1 cells.	2001 May 1	11302700
Decreased susceptibility to ciprofloxacin in Salmonella enterica serotype typhi, United Kingdom.	2001 May-Jun	11384525
Prevalence of serotypes and molecular epidemiology of Streptococcus pneumoniae strains isolated from children in Beijing, China: identification of two novel multiply-resistant clones.	2001 Spring	11310804

Patents

Sample Use Guides

In Vivo Use Guide

Chloramphenicol 0.5% Eye Drops

Route of Administration: Topical

In Vitro Use Guide

The highest activity of chloramphenicol was documented for isolates of Stenotrophomonas maltophilia (76,5 % susceptible, MIC50 = 4 mg/L, MIC90 = 16 mg/L) and of Staphylococcus aureus (76,2 % susceptible, MIC50 = 8 mg/L, MIC90 = 16 mg/L).

Substance Class	Chemical Created by `admin` on `Wed Jul 05 23:18:34 UTC 2023` Edited by `admin` on `Wed Jul 05 23:18:34 UTC 2023`
Record UNII	FMO6OC31WV
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CHLORAMPHENICOL MONOETHANOLAMINE SUCCINATE

Common Name

English

BUTANEDIOIC ACID, COMPD. WITH 2-AMINOETHANOL AND 2,2-DICHLORO-N-((1R,2R)-2-HYDROXY-1-(HYDROXYMETHYL)-2-(4-NITROPHENYL)ETHYL)ACETAMIDE (1:1:1)

Systematic Name

English

SUCCINIC ACID, COMPD. WITH 2-AMINOETHANOL AND 2,2-DICHLORO-N-(.BETA.-HYDROXY-.ALPHA.-(HYDROXYMETHYL)-P-NITROPHENETHYL)ACETAMIDE (1:1:1), D-THREO-(-)-

Systematic Name

English

Code System Code Type Description

PUBCHEM

131801044

Created by admin on Wed Jul 05 23:18:34 UTC 2023 , Edited by admin on Wed Jul 05 23:18:34 UTC 2023

PRIMARY

FDA UNII

FMO6OC31WV

Created by admin on Wed Jul 05 23:18:34 UTC 2023 , Edited by admin on Wed Jul 05 23:18:34 UTC 2023

PRIMARY

CAS

20369-85-1

Created by admin on Wed Jul 05 23:18:34 UTC 2023 , Edited by admin on Wed Jul 05 23:18:34 UTC 2023

PRIMARY

Related Record Type Details


					66974FR9Q1

CHLORAMPHENICOL

PARENT -> SALT/SOLVATE


					AB6MNQ6J6L

SUCCINIC ACID

PARENT -> SALT/SOLVATE


					5KV86114PT

MONOETHANOLAMINE

PARENT -> SALT/SOLVATE

Details

SMILES

InChI

DescriptionSources: http://www.acutetox.eu/pdf_human_short/74-Chloramphenicol%20revised.pdf | https://www.ncbi.nlm.nih.gov/pubmed/20930076

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Cmax

AUC

T1/2

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.acutetox.eu/pdf_human_short/74-Chloramphenicol%20revised.pdf | https://www.ncbi.nlm.nih.gov/pubmed/20930076

C_max

T_1/2

Drug as perpetrator